A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab
Recruiting
Observational Study
Cardiovascular Diseases
Atherosclerotic Cardiovascular Disease
Hypercholesterolemia, Familial
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 99
- Sex
- Any
- Study type
- Observational
- Participants needed
- 5,995 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria:
* A first ever prescription of injection of inclisiran, evolocumab, or alirocumab during the identification period.
* Age ≥18 years at index date.
* With at least 12 months data availability prior to index date.
Exclusion criteria:
• Patients who received either evolocumab or …
Contacts
Novartis Pharmaceuticals
CONTACT